These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33148473)

  • 1. Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Grimm MO; Leucht K
    Eur Urol; 2021 Mar; 79(3):429-430. PubMed ID: 33148473
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Gakis G
    Eur Urol; 2021 May; 79(5):702. PubMed ID: 33390284
    [No Abstract]   [Full Text] [Related]  

  • 3. [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma].
    Le Brun IC; Benderra MA
    Bull Cancer; 2021 Sep; 108(9):784-786. PubMed ID: 34332742
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Srikala S. Sridhar, Thomas Powles, Miguel. Á. Climent Durán, et al. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. Eur Urol 2024:85:154-63.
    Zhou W; Zu X; Hu J
    Eur Urol; 2024 Oct; 86(4):e96. PubMed ID: 38811315
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Catalano M; Santoni M; Roviello G
    Eur Urol; 2024 Sep; 86(3):283. PubMed ID: 38744633
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
    Eur Urol; 2024 Sep; 86(3):282-283. PubMed ID: 38631993
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
    Eur Urol; 2024 Sep; 86(3):280-281. PubMed ID: 38599990
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Shindo T
    Int J Urol; 2024 Aug; 31(8):867-868. PubMed ID: 38752600
    [No Abstract]   [Full Text] [Related]  

  • 9. Maintenance avelumab for metastatic urothelial cancer: a new standard of care.
    Erck A; Aragon-Ching JB
    Cancer Biol Ther; 2020 Dec; 21(12):1095-1096. PubMed ID: 33206587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
    Gupta S; Kamat AM
    Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
    Feng YN; Xie GY; Xiao L
    Eur Urol; 2023 Dec; 84(6):e145. PubMed ID: 37659959
    [No Abstract]   [Full Text] [Related]  

  • 12. Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
    Lapuente M; Conway D; Wood LS; Kehoe K; Carroll Bullock A; Devgan G; Burns KD
    Clin J Oncol Nurs; 2023 Jan; 27(1):71-80. PubMed ID: 37677821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
    Critchlow S; Bullement A; Crabb S; Jones R; Christoforou K; Amin A; Xiao Y; Kapetanakis V; Benedict Á; Chang J; Kearney M; Eccleston A
    Future Oncol; 2024 Mar; 20(8):459-470. PubMed ID: 37529943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
    Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab in locally advanced or metastatic urothelial carcinoma.
    Jackson-Spence F; Szabados B; Toms C; Yang YH; Sng C; Powles T
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):135-140. PubMed ID: 35015593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments.
    Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Yu T; Bharmal M
    Value Health; 2021 Aug; 24(8):1137-1144. PubMed ID: 34372979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    Taguchi S; Kawai T; Nakagawa T; Kume H
    BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
    Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
    Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
    [No Abstract]   [Full Text] [Related]  

  • 19. New treatments for patients with progressive metastatic urothelial carcinoma.
    Rosenberg JE
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):180-183. PubMed ID: 33739967
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.